STOCK TITAN

Fulcrum Therapeutics: ADAR1 reports 8.7% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Fulcrum Therapeutics, Inc. (FULC) is the issuer in a Schedule 13G reporting that ADAR1 Capital Management, LLC, an investment adviser, and its sole manager, Daniel Schneeberger, each report beneficial ownership of 6,648,027 common shares, or 8.7% of the class. The shares are owned directly by private investment funds managed by ADAR1 and may be deemed indirectly beneficially owned by ADAR1 and Schneeberger. Both report shared voting and dispositive power over 6,648,027 shares, with no sole voting or dispositive power. The percentage is based on 76,381,948 shares outstanding as of September 30, 2026.

Beneficially owned shares 6,648,027 shares Reported by ADAR1 Capital Management and Daniel Schneeberger; held directly by investment funds managed by ADAR1
Class ownership 8.7% Based on 76,381,948 shares outstanding as of September 30, 2026
Shares outstanding 76,381,948 shares As of September 30, 2026
Shared voting power 6,648,027 shares Reported by ADAR1 Capital Management and Daniel Schneeberger
Shared dispositive power 6,648,027 shares Reported by ADAR1 Capital Management and Daniel Schneeberger
beneficially owned technical
"Aggregate Amount Beneficially Owned by Each Reporting Person"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared voting power technical
"Shared Voting Power 6,648,027.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power technical
"Shared Dispositive Power 6,648,027.00"
investment adviser regulatory
"an investment adviser as described in"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many FULC shares does ADAR1 report beneficial ownership of?

ADAR1 Capital Management, LLC reports beneficial ownership of 6,648,027 shares, equal to 8.7% of Fulcrum Therapeutics’ common stock. The shares are owned directly by private investment funds managed by ADAR1.

Who directly owns the reported FULC shares?

The 6,648,027 shares are owned directly by private investment funds managed by ADAR1 Capital Management. ADAR1 and its sole manager, Daniel Schneeberger, may be deemed to beneficially own the shares indirectly; both report shared voting and dispositive power.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





359616109

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 6,648,027 shares of common stock, par value $0.001 per share ("Common Stock"), of Fulcrum Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by ADAR1 Capital Management, LLC. The percentage in box 11 is based on 76,381,948 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: The amounts reported in boxes 6, 8, and 9 represent 6,648,027 shares of common stock, par value $0.001 per share ("Common Stock"), of Fulcrum Therapeutics, Inc. (the "Issuer") owned directly by private investment funds managed by ADAR1 Capital Management, LLC. Such securities may be deemed to be indirectly beneficially owned by Daniel Schneeberger, the sole manager of ADAR1 Capital Management, LLC. The percentage in box 11 is based on 76,381,948 shares of Common Stock outstanding as of September 30, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026, filed with the Securities and Exchange Commission on November 12, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:11/16/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:11/16/2026
Exhibit Information

Exhibit A: Joint Filing Agreement

Keep reading